Cargando…
Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases
SCA1, SCA2, and SCA3 are the most common forms of SCAs among the polyglutamine disorders, which include Huntington’s Disease (HD). We investigated the relationship between leukocyte telomere length (LTL) and the phenotype of SCA1, SCA2, and SCA3, comparing them with HD. The results showed that LTL w...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332235/ https://www.ncbi.nlm.nih.gov/pubmed/35892638 http://dx.doi.org/10.3390/antiox11081436 |
_version_ | 1784758596393762816 |
---|---|
author | Scarabino, Daniela Veneziano, Liana Fiore, Alessia Nethisinghe, Suran Mantuano, Elide Garcia-Moreno, Hector Bellucci, Gianmarco Solanky, Nita Morello, Maria Zanni, Ginevra Corbo, Rosa Maria Giunti, Paola |
author_facet | Scarabino, Daniela Veneziano, Liana Fiore, Alessia Nethisinghe, Suran Mantuano, Elide Garcia-Moreno, Hector Bellucci, Gianmarco Solanky, Nita Morello, Maria Zanni, Ginevra Corbo, Rosa Maria Giunti, Paola |
author_sort | Scarabino, Daniela |
collection | PubMed |
description | SCA1, SCA2, and SCA3 are the most common forms of SCAs among the polyglutamine disorders, which include Huntington’s Disease (HD). We investigated the relationship between leukocyte telomere length (LTL) and the phenotype of SCA1, SCA2, and SCA3, comparing them with HD. The results showed that LTL was significantly reduced in SCA1 and SCA3 patients, while LTL was significantly longer in SCA2 patients. A significant negative relationship between LTL and age was observed in SCA1 but not in SCA2 subjects. LTL of SCA3 patients depend on both patient’s age and disease duration. The number of CAG repeats did not affect LTL in the three SCAs. Since LTL is considered an indirect marker of an inflammatory response and oxidative damage, our data suggest that in SCA1 inflammation is present already at an early stage of disease similar to in HD, while in SCA3 inflammation and impaired antioxidative processes are associated with disease progression. Interestingly, in SCA2, contrary to SCA1 and SCA3, the length of leukocyte telomeres does not reduce with age. We have observed that SCAs and HD show a differing behavior in LTL for each subtype, which could constitute relevant biomarkers if confirmed in larger cohorts and longitudinal studies. |
format | Online Article Text |
id | pubmed-9332235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93322352022-07-29 Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases Scarabino, Daniela Veneziano, Liana Fiore, Alessia Nethisinghe, Suran Mantuano, Elide Garcia-Moreno, Hector Bellucci, Gianmarco Solanky, Nita Morello, Maria Zanni, Ginevra Corbo, Rosa Maria Giunti, Paola Antioxidants (Basel) Article SCA1, SCA2, and SCA3 are the most common forms of SCAs among the polyglutamine disorders, which include Huntington’s Disease (HD). We investigated the relationship between leukocyte telomere length (LTL) and the phenotype of SCA1, SCA2, and SCA3, comparing them with HD. The results showed that LTL was significantly reduced in SCA1 and SCA3 patients, while LTL was significantly longer in SCA2 patients. A significant negative relationship between LTL and age was observed in SCA1 but not in SCA2 subjects. LTL of SCA3 patients depend on both patient’s age and disease duration. The number of CAG repeats did not affect LTL in the three SCAs. Since LTL is considered an indirect marker of an inflammatory response and oxidative damage, our data suggest that in SCA1 inflammation is present already at an early stage of disease similar to in HD, while in SCA3 inflammation and impaired antioxidative processes are associated with disease progression. Interestingly, in SCA2, contrary to SCA1 and SCA3, the length of leukocyte telomeres does not reduce with age. We have observed that SCAs and HD show a differing behavior in LTL for each subtype, which could constitute relevant biomarkers if confirmed in larger cohorts and longitudinal studies. MDPI 2022-07-24 /pmc/articles/PMC9332235/ /pubmed/35892638 http://dx.doi.org/10.3390/antiox11081436 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Scarabino, Daniela Veneziano, Liana Fiore, Alessia Nethisinghe, Suran Mantuano, Elide Garcia-Moreno, Hector Bellucci, Gianmarco Solanky, Nita Morello, Maria Zanni, Ginevra Corbo, Rosa Maria Giunti, Paola Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases |
title | Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases |
title_full | Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases |
title_fullStr | Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases |
title_full_unstemmed | Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases |
title_short | Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases |
title_sort | leukocyte telomere length variability as a potential biomarker in patients with polyq diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332235/ https://www.ncbi.nlm.nih.gov/pubmed/35892638 http://dx.doi.org/10.3390/antiox11081436 |
work_keys_str_mv | AT scarabinodaniela leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT venezianoliana leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT fiorealessia leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT nethisinghesuran leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT mantuanoelide leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT garciamorenohector leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT belluccigianmarco leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT solankynita leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT morellomaria leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT zanniginevra leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT corborosamaria leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases AT giuntipaola leukocytetelomerelengthvariabilityasapotentialbiomarkerinpatientswithpolyqdiseases |